{'fraction_non_alphanumeric': 0.040339702760084924, 'fraction_numerical': 0.02335456475583864, 'mean_word_length': 5.883211678832117, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Low levels of minimal residual disease after induction chemotherapy for BCR‐ABL1‐negative acute lymphoblastic leukaemia in adults are clinically relevant

The aim of the present study was to evaluate the significance of low‐level minimal/measurable residual disease (MRD) during early consolidation treatment in adult BCR‐ABL1–negative acute lymphoblastic leukaemia. The MRD load was monitored by immunoglobulin/T‐cell receptor rearrangements and assessed as negative [complete MRD response (CMR)], positive non‐quantifiable (MRDnq) and positive quantifiable (MRDq). MRDnq before the first and second consolidation blocks had a comparable negative effect on survival as MRDq. The 5‐year overall survival for CMR, MRDnq and MRDq at week 11 was 74·0%, 42·3% and 35·0% respectively. No central nervous system infiltration and MRD at week 11 were independent prognostic factors for survival on multivariate analysis (hazard ratios 0·32 and 2·25).